DOCSLIB.ORG

TC 1600 Iprs.Xlsx

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
TC 1600 Iprs.Xlsx Drug (if Trial Patent No. Filed Date Petitioner(s) Patent Owner(s) Inst. Dec. Outcome Details of FWD applicable) <Information obtained primarily from Lex Machina™ and public sources on the Internet. If any errors are identified, please contact Lisa Mandrusiak at Oblon.> Enzymotec USA, Inc.; Enzymtoec Ltd.; Aker Neptune Technologies & IPR2014-00003 8,278,351 1-Oct-13 BioMarien ASA Bioressources Inc. Instituted Final written decision Some claims upheld Apotex Holdings, Inc.; IPR2014-00115 Tygacil® 7,879,828 1-Nov-13 Apotex Inc. Wyeth LLC Instituted Final written decision All inst. claims upheld Neptune Technologies & IPR2014-00126 8,383,675 7-Nov-13 Aker BioMarine ASA Bioressources Inc. N/A Settled pre-institution N/A Amneal Pharmaceuticals LLC; Amneal Pharmaceuticals of IPR2014-00160 Opana® ER 7,851,482 18-Nov-13 New York LLC Endo Pharmaceuticals, Inc. Instituted Claims disclaimed N/A IPR2014-00315 8,318,738 31-Dec-13 PRISM Pharma Co., Ltd. CHOONGWAE PHARMA CORP. N/A Settled pre-institution N/A BioDelivery Sciences IPR2014-00325 Suboxone® 8,475,832 15-Jan-14 International, Inc. RB Pharmaceuticals Ltd. Instituted Final written decision All inst. claims unpatentable EI Dupont De Nemours and IPR2014-00331 8,312,672 8-Jan-14 Co. Monsanto Technology LLC Denied N/A N/A EI Dupont De Nemours and IPR2014-00332 8,071,845 8-Jan-14 Co. Monsanto Technology LLC Denied N/A N/A EI Dupont De Nemours and IPR2014-00333 7,832,143 8-Jan-14 Co. Monsanto Technology LLC Denied N/A N/A IPR2014-00360 Opana® ER 8,329,216 16-Jan-14 Amneal Pharmaceuticals LLC Endo Pharmaceuticals, Inc. Instituted Final written decision All inst. claims upheld IPR2014-00361 Opana® ER 8,309,122 16-Jan-14 Amneal Pharmaceuticals LLC Endo Pharmaceuticals, Inc. Denied Time barred N/A Onsolis™; Bunavail™; IPR2014-00376 Belbuca™ 7,579,019 22-Jan-14 MonoSol Rx LLC Arius Two, Inc. Instituted Final written decision All inst. claims upheld Proquin® XR; Glumetza®; Gralise®; Janumet® XR; IPR2014-00377 Jentadueto® XR 6,635,280 24-Jan-14 Purdue Pharma L.P. Depomed, Inc. Instituted Final written decision All inst. claims upheld Proquin® XR; Glumetza®; Gralise®; Janumet® XR; IPR2014-00378 Jentadueto® XR 6,340,475 24-Jan-14 Purdue Pharma L.P. Depomed, Inc. Instituted Final written decision All inst. claims upheld Proquin® XR; Glumetza®; Gralise®; Janumet® XR; IPR2014-00379 Jentadueto® XR 6,340,475 24-Jan-14 Purdue Pharma L.P. Depomed, Inc. Instituted Final written decision All inst. claims upheld Enviro Tech Cehmical IPR2014-00382 7,728,132 27-Jan-14 LENROC COMPANY Services, Inc. Denied N/A N/A IPR2014-00398 8,299,032 31-Jan-14 3-D Matrix, Ltd. Menicon Co. Ltd. Denied N/A N/A Vireo Systems, Inc; Board of Complete Nutrition Holdings Regents of the University of IPR2014-00451 8,354,450 20-Feb-14 Inc. Nebraska Instituted Settled post-institution N/A Neptune Technologies & IPR2014-00466 8,383,675 27-Feb-14 Enzymotec Ltd. Bioressources Inc. N/A Settled pre-institution N/A IPR2014-00506 6,974,569 12-Mar-14 Conopco, Inc. dba Unilever The Procter & Gamble Co. Denied N/A N/A IPR2014-00507 6,451,300 12-Mar-14 Conopco, Inc. dba Unilever The Procter & Gamble Co. Denied N/A N/A University of Washington; Oxford Nanopore UAB Research Foundation; IPR2014-00512 8,673,550 18-Mar-14 Technologies Ltd. The Illumina, Inc. Denied N/A N/A University of Washington; Oxford Nanopore UAB Research Foundation; Claims disclaimed; final IPR2014-00513 8,673,550 18-Mar-14 Technologies Ltd. The Illumina, Inc. Instituted written decision Some claims upheld Noven Pharmaceuticals, Inc.; Novartis AG; LTS Lohmann IPR2014-00549 Exelon® 6,316,023 2-Apr-14 Mylan Pharmaceuticals, Inc. Therapie-Systeme AG Instituted Final written decision All inst. claims unpatentable Noven Pharmaceuticals, Inc.; LTS Lohmann Therapie- IPR2014-00550 Exelon® 6,335,031 2-Apr-14 Mylan Pharmaceuticals, Inc. Systeme AG; Novartis AG Instituted Final written decision All inst. claims unpatentable IPR2014-00559 6,448,274 1-Apr-14 Torrent Pharmaceuticals Ltd. Merck Frosst Canada & Co. Denied N/A N/A Enzymotec Ltd.; Enzymotec Neptune Technologies & IPR2014-00556 8,278,351 4-Apr-14 USA, Inc. Bioressources Inc. Instituted Final written decision All inst. claims unpatentable Butamax (TM) Advanced IPR2014-00581 8,273,565 4-Apr-14 Biofules LLC Gevo Inc. Denied N/A N/A Neptune Technologies & IPR2014-00586 8,278,351 11-Apr-14 Enzymotec Ltd. Bioressources Inc. N/A Settled pre-institution N/A IPR2014-00628 6,649,155 15-Apr-14 Conopco, Inc. dba Unilever The Procter & Gamble Co. Denied N/A N/A Neptune Technologies & IPR2014-00636 8,278,351 23-Apr-14 Enzymotec Ltd. Bioressources Inc. N/A Settled pre-institution N/A Glumetza®; Gralise®; IPR2014-00651 Invokamet® XR 6,723,340 17-Apr-14 Endo Pharmaceuticals, Inc. Depomed, Inc. Denied N/A N/A Glumetza®; Gralise®; IPR2014-00652 Invokamet® XR 6,723,340 17-Apr-14 Endo Pharmaceuticals, Inc. Depomed, Inc. Instituted Final written decision All inst. claims unpatentable Proquin® XR; Glumetza®; Gralise®; Janumet® XR; IPR2014-00653 Jentadueto® XR 6,340,475 17-Apr-14 Endo Pharmaceuticals, Inc. Depomed, Inc. Denied N/A N/A Proquin® XR; Glumetza®; Gralise®; Janumet® XR; IPR2014-00654 Jentadueto® XR 6,340,475 17-Apr-14 Endo Pharmaceuticals, Inc. Depomed, Inc. Instituted Final written decision All inst. claims upheld Proquin® XR; Glumetza®; Gralise®; Janumet® XR; IPR2014-00655 Jentadueto® XR 6,635,280 17-Apr-14 Endo Pharmaceuticals, Inc. Depomed, Inc. Denied N/A N/A Proquin® XR; Glumetza®; Gralise®; Janumet® XR; IPR2014-00656 Jentadueto® XR 6,635,280 17-Apr-14 Endo Pharmaceuticals, Inc. Depomed, Inc. Instituted Final written decision All inst. claims upheld IPR2014-00676 8,337,856 17-Apr-14 Phigenix, Inc. ImmunoGen, Inc. Instituted Final written decision All inst. claims upheld Los Angeles Biomedical Research Inst. at Harbor-UCLA IPR2014-00693 8,133,903 25-Apr-14 Lilly USA, LLC; Eli Lilly & Co. Medical Center Instituted Final written decision All inst. claims upheld IPR2014-00731 Astepro™ 8,071,073 7-May-14 Impax Laboratories, Inc. Meda Pharmaceuticals Inc. N/A Settled pre-institution N/A Lucerne Biosciences, LLC; LCS IPR2014-00739 8,318,813 9-May-14 Shire Development LLC Group, LLC Instituted Claims disclaimed N/A Los Angeles Biomedical Research Inst. at Harbor-UCLA IPR2014-00752 8,133,903 13-May-14 Lilly USA, LLC; Eli Lilly & Co. Medical Center Instituted Final written decision All inst. claims unpatentable Torrent Pharmaceuticals Ltd.; Mylan Pharmaceuticals, Inc.; Mitsubishi Tanabe Pharma IPR2014-00784 Gilenya™ 8,324,283 27-May-14 Apotex Inc. Corp.; Novartis AG Instituted Final written decision All inst. claims unpatentable IPR2014-00796 5,989,569 21-May-14 CAO Group The Procter & Gamble Co. Denied N/A N/A IPR2014-00797 6,045,811 21-May-14 CAO Group The Procter & Gamble Co. Denied N/A N/A IPR2014-00798 7,122,199 21-May-14 CAO Group The Procter & Gamble Co. Denied N/A N/A ImmunoGen, Inc.; Genentech, IPR2014-00842 7,575,748 29-May-14 Phigenix, Inc. Inc. Denied N/A N/A IPR2014-00868 Glucotrol XL® RE44459 30-May-14 PACK Pharmaceuticals, LLC Alza Corporation N/A Settled pre-institution N/A Trizivir®; Epzicom®; ViiV Healthcare Co.; Viiv IPR2014-00876 Triumeq® 6,417,191 2-Jun-14 Apotex Inc. Healthcare UK Ltd. Instituted Settled post-institution N/A Viread™; Truvada®; IPR2014-00885 Atripla® 5,922,695 4-Jun-14 Mylan Pharmaceuticals, Inc. Gilead Sciences, Inc. Denied N/A N/A Viread™; Truvada®; IPR2014-00886 Atripla® 5,935,946 4-Jun-14 Mylan Pharmaceuticals, Inc. Gilead Sciences, Inc. Denied N/A N/A Viread™; Truvada®; IPR2014-00887 Atripla® 5,977,089 4-Jun-14 Mylan Pharmaceuticals, Inc. Gilead Sciences, Inc. Denied N/A N/A Viread™; Truvada®; IPR2014-00888 Atripla® 6,043,230 4-Jun-14 Mylan Pharmaceuticals, Inc. Gilead Sciences, Inc. Denied N/A N/A Baxter Healthcare Corp; Grifols, Inc.; Grifols S.A.; IPR2014-00899 6,462,180 4-Jun-14 Kamada, Ltd. Grifols Therapeutics, Inc. Instituted Final written decision All inst. claims unpatentable IPR2014-00929 6,372,428 10-Jun-14 Luminex Corp. Irori Technologies, Inc. Instituted Settled post-institution N/A IPR2014-00930 6,416,714 10-Jun-14 Luminex Corp. Irori Technologies, Inc. Instituted Settled post-institution N/A IPR2014-00931 6,352,854 10-Jun-14 Luminex Corp. Irori Technologies, Inc. Instituted Settled post-institution N/A IPR2014-00932 6,352,854 10-Jun-14 Luminex Corp. Irori Technologies, Inc. Instituted Settled post-institution N/A IPR2014-00933 6,352,854 10-Jun-14 Luminex Corp. Irori Technologies, Inc. Instituted Settled post-institution N/A Enviro Granulation, LTD; Plant IPR2014-00939 6,884,756 11-Jun-14 Science, Inc. The Andersons, Inc. Denied N/A N/A Enviro Granulation, LTD; Plant IPR2014-00941 8,574,631 11-Jun-14 Science, Inc. The Andersons, Inc. Denied N/A N/A BioDelivery Sciences IPR2014-00998 Suboxone® 8,475,832 20-Jun-14 International, Inc. RB Pharmaceuticals Ltd. Denied N/A N/A Senju Pharmaceutical Co.; Johnson Mattey Inc.; Mayne Bausch & Lomb Pharma Pharma Group Ltd.; Metrics, Holdings Copr.; Bausch & IPR2014-01041 Prolensa® 8,129,431 26-Jun-14 Inc. Lomb Inc. Instituted Settled post-institution N/A Senju Pharmaceutical Co.; Johnson Mattey Inc.; Mayne Bausch & Lomb Pharma Pharma Group Ltd.; Metrics, Holdings Copr.; Bausch & IPR2014-01043 Prolensa® 8,669,290 26-Jun-14 Inc. Lomb Inc. Instituted Settled post-institution N/A LEO Pharma, Inc.; LEO Pharma Medac Gesellschaft Fur IPR2014-01091 Rasuvo® 8,664,231 1-Jul-14 A/S; Antares Pharma Inc. Klinische Instituted Settled post-institution N/A IPR2014-01093 7,955,794 2-Jul-14 Ariosa Diagnostics, Inc.
Load more

Recommended publications
  • Symbols Alexian Brothers Health System Index to Nov P
    Volume 19, Index December 2014 Symbols Alexian Brothers Health System Index to Nov p. 2 Health Care M&A News 1-800-CONTACTS Feb p. 18 A&L Goodbody Apr p. 16, July p. 16 All Care Home Health, LLC Feb p. 17 Each company and orga- A Allergan Inc. Feb p. 10, May p. 1, nization discussed in Health May p. 19, Jun p. 15, July p. 3, Care M&A News, from Janu- Abbott Labs July p. 3, Aug p. 17, July p. 10, Sept p. 16, Oct p. 3, ary through December 2014, Dec p. 4 Nov p. 1, Dec p. 4, Dec p. 16, is listed alphabetically here. AbbVie Inc. July p. 3, July p. 16, Dec p. 19 References are typically to Aug p. 9, Oct p. 2, Oct p. 16, Allscripts Feb p. 2, Apr p. 10 the first occurrence of the Nov p. 19, Dec p. 2 AllSpire Health Partners Nov p. 2 company’s or organiza- ABL, Inc. Aug p. 18 All Staffing Services Jan p. 17 tion’s name in the pertinent Acadia Healthcare Company Feb p. 16, Almost Family, Inc. Apr p. 16 issue; further discussion July p. 17, Oct p. 17, Nov p. 17 ALN Medical Management, LLC may follow later in the text Accelera Innovations, Inc. Jan p. 17 Accelrys, Inc. Jan p. 15 Feb p. 8 but is not indicated here. AccessClosure, Inc. May p. 15 Alta Partners Jun p. 16 Achillion Pharmaceuticals July p. 17 Altos Solutions, Inc. Jun p. 15 References are sorted by Actavis (Foshan) Pharmaceuticals Co.
    [Show full text]
  • NASDAQ Stock Market
    Nasdaq Stock Market Friday, December 28, 2018 Name Symbol Close 1st Constitution Bancorp FCCY 19.75 1st Source SRCE 40.25 2U TWOU 48.31 21st Century Fox Cl A FOXA 47.97 21st Century Fox Cl B FOX 47.62 21Vianet Group ADR VNET 8.63 51job ADR JOBS 61.7 111 ADR YI 6.05 360 Finance ADR QFIN 15.74 1347 Property Insurance Holdings PIH 4.05 1-800-FLOWERS.COM Cl A FLWS 11.92 AAON AAON 34.85 Abiomed ABMD 318.17 Acacia Communications ACIA 37.69 Acacia Research - Acacia ACTG 3 Technologies Acadia Healthcare ACHC 25.56 ACADIA Pharmaceuticals ACAD 15.65 Acceleron Pharma XLRN 44.13 Access National ANCX 21.31 Accuray ARAY 3.45 AcelRx Pharmaceuticals ACRX 2.34 Aceto ACET 0.82 Achaogen AKAO 1.31 Achillion Pharmaceuticals ACHN 1.48 AC Immune ACIU 9.78 ACI Worldwide ACIW 27.25 Aclaris Therapeutics ACRS 7.31 ACM Research Cl A ACMR 10.47 Acorda Therapeutics ACOR 14.98 Activision Blizzard ATVI 46.8 Adamas Pharmaceuticals ADMS 8.45 Adaptimmune Therapeutics ADR ADAP 5.15 Addus HomeCare ADUS 67.27 ADDvantage Technologies Group AEY 1.43 Adobe ADBE 223.13 Adtran ADTN 10.82 Aduro Biotech ADRO 2.65 Advanced Emissions Solutions ADES 10.07 Advanced Energy Industries AEIS 42.71 Advanced Micro Devices AMD 17.82 Advaxis ADXS 0.19 Adverum Biotechnologies ADVM 3.2 Aegion AEGN 16.24 Aeglea BioTherapeutics AGLE 7.67 Aemetis AMTX 0.57 Aerie Pharmaceuticals AERI 35.52 AeroVironment AVAV 67.57 Aevi Genomic Medicine GNMX 0.67 Affimed AFMD 3.11 Agile Therapeutics AGRX 0.61 Agilysys AGYS 14.59 Agios Pharmaceuticals AGIO 45.3 AGNC Investment AGNC 17.73 AgroFresh Solutions AGFS 3.85
    [Show full text]
  • DCAT MEMBER COMPANY MEETING LOCATOR V. 4
    DCAT MEMBER COMPANY MEETING LOCATOR v. 4 THE BENJAMIN Sancilio Pharmaceuticals Company, Inc. Sri Krishna Pharmaceuticals Ltd. Amino Chemicals Ltd. Zydus Pharmaceuticals (USA) Inc. Apogee Pharma, Inc. C2 PHARMA INTERCONTINENTAL BARCLAY Calyx Chemicals & Pharmaceuticals Ltd. AbbVie* ChemCon GmbH ACIC Pharmaceuticals Inc. Concord Biotech Limited Advitech SA Dipharma Francis Srl Amneal Pharmaceuticals LLC DSM Sinochem Pharmaceuticals ALP Pharm F.I.S. - Fabbrica Italiana Sintetici S.p.A. AMRI Jost Chemical Co. Asymchem Inc. Jubilant Pharma Capsugel, Now a Lonza Company* PharmSource, A GlobalData Company CBC AMERICAS Corp. PolyPeptide Group CellMark USA, LLC ROHNER Inc. Charioteer Pharmaceutical Co., Ltd., Zhejiang FIFTY NYC, A AFFINA HOTEL Chemical and Pharmaceutical Solutions Chiral Quest Corp. Chartwell Pharmaceuticals, LLC Croda, Inc. HOTEL 48LEX DFE Pharma AB BioTechnologies, Inc. DPL-US AiPing Pharmaceutical, Inc. EQ Esteve Almac Evonik Corporation Aptuit LLC FAREVA SA AZAD Fine Chemicals Ltd. Flavine North America, Inc. Cambridge Isotope Laboratories, Inc. Formosa Laboratories, Inc. CMC Biologics Grifols International S.A. Groupe Parima Hainan Poly Pharm. Co., Ltd. Navin Fluorine International Limited Harris Pharmaceutical Qualicaps, Inc. Helm AG RC2 Pharma Connect LLC Hetero USA, Inc. Recipharm Hikal, Ltd. Recro Gainesville LLC Interchem Corporation Reed-Lane, Inc. Inventia Healthcare PVT LTD Please note: Some DCAT member companies have requested not to be listed in the locator. (*) indicates member companies with Business Meeting Spaces in more than one hotel. INTERCONTINENTAL BARCLAY CONT'D PiSA BioPharm, Inc. SPI Pharma Inc. Johnson Matthey Tapemark Kingchem Life Science LLC Unither Pharmaceutical Legacy Pharmaceutical Packaging Uquifa S.A. Lonza AG* Neuland Laboratories Ltd. LOTTE NY PALACE Orion Group AbbVie* Par Pharmaceutical, Inc.
    [Show full text]
  • BTG INTERNATIONAL LIMITED V. AMNEAL PHARMACEUTICALS LLC
    United States Court of Appeals for the Federal Circuit ______________________ BTG INTERNATIONAL LIMITED, JANSSEN BIOTECH, INC., JANSSEN ONCOLOGY, INC., JANSSEN RESEARCH & DEVELOPMENT, LLC, Plaintiffs-Appellants v. AMNEAL PHARMACEUTICALS LLC, AMNEAL PHARMACEUTICALS OF NEW YORK, LLC, DR. REDDY'S LABORATORIES, INC., DR. REDDY'S LABORATORIES, LTD., WOCKHARDT BIO AG, WOCKHARDT USA LLC, WOCKHARDT LTD., MYLAN PHARMACEUTICALS INC., MYLAN INC., WEST-WARD PHARMACEUTICALS CORP., NKA HIKMA PHARMACEUTICALS USA INC., HIKMA PHARMACEUTICALS LLC, TEVA PHARMACEUTICALS USA, INC., Defendants-Appellees PAR PHARMACEUTICAL, INC., PAR PHARMACEUTICAL COMPANIES, INC., RISING PHARMACEUTICALS, INC., Defendants ______________________ 2019-1147 ______________________ Appeal from the United States District Court for the District of New Jersey in Nos. 2:15-cv-05909-KM-JBC, 2:16-cv-02449-KM-JBC, 2:17-cv-06435-KM-JBC, Judge Kevin McNulty. 2 BTG INTERNATIONAL LIMITED v. AMNEAL PHARMACEUTICALS LLC - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - BTG INTERNATIONAL LIMITED, JANSSEN BIOTECH, INC., JANSSEN ONCOLOGY, INC., JANSSEN RESEARCH & DEVELOPMENT, LLC, Plaintiffs-Appellants v. AMERIGEN PHARMACEUTICALS, INC., AMERIGEN PHARMACEUTICALS LIMITED, Defendants-Appellees ______________________ 2019-1148 ______________________ Appeal from the United States District Court for the District of New Jersey in No. 2:16-cv-02449-KM-JBC, Judge Kevin McNulty. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - JANSSEN
    [Show full text]
  • Second-Quarter Biotech Job Picture
    CAREERS AND RECRUITMENT Second-quarter biotech job picture Michael Francisco n May, Merck (Kenilworth, NJ, USA) announced it would invest $310 investment capital. The first 13 life science companies in residence were Imillion over the next three years to expand two sites in Ireland—a announced, eight of which are focused on therapeutics and drug discov- biologics facility in Brinny, County Cork, and a vaccines and biologics ery: aratinga.bio, Chimeron Bio, Hookipa Biotech, ENB Therapeutics, plant in Carlow Town, County Carlow—with plans to add 330 jobs in Beagle Bioscience, Sevengenes, Gotham Therapeutics and Renovo total. The Carlow facility is a key production site for the cancer drug Pharmaceuticals. Keytruda (pembrolizumab), which was recently approved by the US And Lexington, Massachusetts–based Agenus said it will shutter its Food and Drug Administration. Just last year, the drugmaker said it site in Basel, Switzerland, and consolidate operations to Cambridge, would add 110 jobs at its plant in Carlow and another 50 positions to UK, and Lexington, as well as focus on its manufacturing operations its operations in Cork. in Berkeley, California. The company will reduce head count by about Last month saw the opening of Alexandria LaunchLabs in the 50 employees. Alexandria Center for Life Science in New York City, as part of a Advertised biotech and pharmaceutical sector jobs in the job data- nearly $1.2-billion joint effort by the city and state of New York to spur bases tracked by Nature Biotechnology during the second quarter of development in the life sciences. LaunchLabs is designed to provide 2017 are shown in Tables 1 and 2.
    [Show full text]
  • Annual Report
    ANNUAL REPORT 2019 MARCH 2020 To Our Shareholders Alex Gorsky Chairman and Chief Executive Officer By just about every measure, Johnson & These are some of the many financial and Johnson’s 133rd year was extraordinary. strategic achievements that were made possible by the commitment of our more than • We delivered strong operational revenue and 132,000 Johnson & Johnson colleagues, who adjusted operational earnings growth* that passionately lead the way in improving the health exceeded the financial performance goals we and well-being of people around the world. set for the Company at the start of 2019. • We again made record investments in research and development (R&D)—more than $11 billion across our Pharmaceutical, Medical Devices Propelled by our people, products, and and Consumer businesses—as we maintained a purpose, we look forward to the future relentless pursuit of innovation to develop vital with great confidence and optimism scientific breakthroughs. as we remain committed to leading • We proudly launched new transformational across the spectrum of healthcare. medicines for untreated and treatment-resistant diseases, while gaining approvals for new uses of many of our medicines already in the market. Through proactive leadership across our enterprise, we navigated a constant surge • We deployed approximately $7 billion, of unique and complex challenges, spanning primarily in transactions that fortify our dynamic global issues, shifting political commitment to digital surgery for a more climates, industry and competitive headwinds, personalized and elevated standard of and an ongoing litigious environment. healthcare, and that enhance our position in consumer skin health. As we have experienced for 133 years, we • And our teams around the world continued can be sure that 2020 will present a new set of working to address pressing public health opportunities and challenges.
    [Show full text]
  • JMP Securities Healthcare Conference to Be Held in New York
    JMP Securities Healthcare Conference to Be Held in New York SAN FRANCISCO, Oct 01, 2008 (BUSINESS WIRE) -- JMP Group Inc. (NYSE:JMP), an investment banking and alternative asset management firm, announced today that its broker-dealer subsidiary, JMPSecurities, will host the third annual JMP Securities Healthcare Focus Conference at Le Parker Meridien in New York on Monday and Tuesday, October 6 and 7, 2008. The two-day conference will feature presentations by senior executives of nearly 90 public and private companies in the biotechnology, medical devices and healthcare services industries before an audience of institutional investors and financial sponsors. For additional details or to register to attend the event, visit www.jmpsecurities.com/about/events.html or www.twstevent.com/jmp.html. Companies scheduled to present as of September 30, 2008; subject to change: A.D.A.M., Inc. ACADIA Pharmaceuticals Inc. Acceleron Pharma, Inc. Achillion Pharmaceuticals, Inc. Alexza Pharmaceuticals, Inc. Allos Therapeutics, Inc. Allscripts Healthcare Solutions, Inc. Alnylam Pharmaceuticals, Inc. American CareSource Holdings, Inc. Anadys Pharmaceuticals, Inc. ARCA biopharma, Inc. Ardea Biosciences, Inc. athenahealth Inc. AtriCure, Inc. AVEO Pharmaceuticals, Inc. AVI BioPharma, Inc. BioCryst Pharmaceuticals, Inc. C. R. Bard, Inc. Cadence Pharmaceuticals, Inc. Celera Corporation Celgene Corporation Celleration, Inc. Cerus Corporation Chem Rx Corporation Concert Pharmaceuticals, Inc. Corcept Therapeutics Incorporated Cypress Bioscience, Inc. Cytokinetics, Incorporated DexCom, Inc. DiagnoCure Inc. Dialysis Corporation of America Echo Therapeutics, Inc. Eclipsys Corp. Enanta Pharmaceuticals, Inc. Endocare Inc. Exelixis, Inc. EyeGate Pharmaceuticals, Inc. Genomic Health, Inc. Given Imaging, Ltd. HeartWare Limited Horizon Therapeutics, Inc. Human Genome Sciences, Inc. HydroCision, Inc. Idenix Pharmaceuticals, Inc. Idera Pharmaceuticals, Inc.
    [Show full text]
  • Complaint 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
    1 Geoffrey D. Strommer (AK Bar # 0911044) Dawn E. Winalski (AK Bar # 1311107) 2 Edmund Clay Goodman (pro hac vice admission pending) Hobbs, Straus, Dean & Walker, LLP 3 516 SE Morrison Street, Suite 1200 4 Portland, OR 97214 Phone: (503) 242­1745 5 Fax: (503) 242­1072 Email: [email protected] 6 Email: [email protected] 7 Email: [email protected] 8 Attorneys for SouthEast Alaska Regional Health Consortium 9 10 11 UNITED STATES DISTRICT COURT 12 DISTRICT OF ALASKA 13 14 SOUTHEAST ALASKA REGIONAL Case No.: 3:18-cv-00217-TMB HEALTH CONSORTIUM, 15 COMPLAINT 16 Plaintiff, JURY TRIAL DEMANDED 17 vs. 18 PURDUE PHARMA L.P.; PURDUE 19 PHARMA INC.; THE PURDUE FREDERICK COMPANY; RHODES 20 PHARMACEUTICALS, L.P.; RHODES TECHNOLOGIES, INC.; CEPHALON, 21 INC.; TEVA PHARMACEUTICAL 22 INDUSTRIES, LTD.; TEVA PHARMACEUTICALS USA, INC; 23 JANSSEN PHARMACEUTICALS, INC.; ORTHO­MCNEIL­JANSSEN 24 PHARMACEUTICALS, INC. N/K/A 25 JANSSEN PHARMACEUTICALS, INC.; JANSSEN PHARMACEUTICA, INC. 26 N/K/A JANSSEN PHARMACEUTICALS, INC.; NORAMCO, INC.; ENDO HEALTH 27 SOLUTIONS INC.; ENDO COMPLAINT Case 3:18-cv-00217-TMB Document 1 Filed 09/20/18 Page 1 of 163 1 PHARMACEUTICALS INC.; ENDO INTERNATIONAL PLC; PAR 2 PHARMACEUTICAL, INC.; PAR PHARMACEUTICALS COMPANIES, 3 INC. F/K/A PAR PHARMACEUTICAL 4 HOLDINGS, INC.; ALLERGAN PLC F/K/A ACTAVIS PLC; ALLERGAN 5 FINANCE LLC, F/K/A ACTAVIS, INC., F/K/A WATSON PHARMACEUTICALS, 6 INC.; WATSON LABORATORIES, INC.; 7 ACTAVIS LLC; ACTAVIS PHARMA, INC. F/K/A WATSON PHARMA, INC.; 8 INSYS THERAPEUTICS, INC.; MALLINCKRODT PLC; 9 MALLINCKRODT, LLC; SPECGX LLC; 10 ABBOTT LABORATORIES; ABBOTT LABORATORIES, INC; AMNEAL 11 PHARMACEUTICALS, INC F/K/A AMNEAL PHARMACEUTICALS, LLC; 12 KVK­TECH, INC.; MCKESSON CORP.; 13 CARDINAL HEALTH, INC.; CARDINAL HEALTH 110, LLC; 14 AMERISOURCEBERGEN CORP.; ANDA, INC.; ANDA PHARMACEUTICALS, 15 INC.; HENRY SCHEIN, INC.; HENRY 16 SCHEIN MEDICAL SYSTEMS, INC.; and JOHN & JANE DOES 1­100 INCLUSIVE, 17 Defendants.
    [Show full text]
  • Local Laboratory Testing of Germline BRCA Mutations Vs. Myriad: a Single-Institution Experience in Korea
    diagnostics Article Local Laboratory Testing of Germline BRCA Mutations vs. Myriad: A Single-Institution Experience in Korea Joohyun Hong 1 , Jiyun Lee 1, Minsuk Kwon 1, Ji-Yeon Kim 1, Jong-Won Kim 2 , Jin Seok Ahn 1, Young-Hyuck Im 1 and Yeon Hee Park 1,* 1 Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea; [email protected] (J.H.); [email protected] (J.L.); [email protected] (M.K.); [email protected] (J.-Y.K.); [email protected] (J.S.A.); [email protected] (Y.-H.I.) 2 Department of Laboratory Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea; [email protected] * Correspondence: [email protected]; Tel.: +82-2-3410-1780 Abstract: Genetic diagnosis for human epidermal growth factor receptor 2-negative metastatic breast cancer patients with the germline BRCA (gBRCA) mutation has been emphasized since the development of polyadenosine diphosphate-ribose polymerase inhibitors. Myriad Genetics, Inc.’s (Salt Lake City, UT, USA) companion diagnostics service is almost exclusively used for genetic testing. The aim of this study was to compare the results of germline BRCA mutation tests returned by a local laboratory and those performed by Myriad. Between April 2014 and February 2018, 31 patients with gBRCA 1/2 mutation test results from both Samsung Medical Center (Seoul, Korea) and Myriad were enrolled. “Discordant: Opposite classification” was observed for only one among 27 (3.7%). Citation: Hong, J.; Lee, J.; Kwon, M.; This discrepancy was due to the detection of a deleterious large genomic rearrangement of BRCA 1 Kim, J.-Y.; Kim, J.-W.; Ahn, J.S.; Im, by Myriad.
    [Show full text]
  • Matthew Kessman, Et Al. V. Myriad Genetics, Et Al. 18-CV-00336
    Case 2:18-cv-00336-DAK-EJF Document 30 Filed 08/31/18 Page 1 of 34 UNITED STATES DISTRICT COURT DISTRICT OF UTAH ) MATTHEW KESSMAN, Individually and ) on Behalf of All Others Similarly Situated, ) Case No. 2:18-cv-00336 ) Plaintiff, ) AMENDED CLASS ACTION ) COMPLAINT v. ) ) ) MYRIAD GENETICS, INC., MARK ) JURY TRIAL DEMANDED CHRISTOPHER CAPONE, PETER D. ) MELDRUM, R. BRYAN RIGGSBEE, and ) ) JAMES S. EVANS, ) ) Defendants. ) Case 2:18-cv-00336-DAK-EJF Document 30 Filed 08/31/18 Page 2 of 34 TABLE OF CONTENTS I. INTRODUCTION .............................................................................................................. 1 II. JURISDICTION AND VENUE ......................................................................................... 4 III. PARTIES ............................................................................................................................ 5 IV. SUBSTANTIVE ALLEGATIONS .................................................................................... 6 A. Company Background ............................................................................................ 6 B. Myriad’s BRCA1 and BRCA2 Testing .................................................................. 6 C. The HCPCS Coding System ................................................................................... 8 D. Coding of Myriad’s Genetic Tests ........................................................................ 10 E. Myriad Systematically Overbilled Medicare for Its Testing ................................ 11
    [Show full text]
  • Preliminary Healthcare Agenda 01.03X
    29th Annual J.P. Morgan Healthcare Conference January 10 - 13, 2011 Westin St. Francis Hotel, San Francisco, CA Preliminary Conference Agenda SUNDAY, JANUARY 9 - Registration in Tower Salon A - 3 to 9 PM MONDAY, JANUARY 10 - Registration in Tower Salon A - 6:45 AM, Breakfast in Italian Foyer Grand Ballroom Colonial Room California West California East Elizabethan A/B Elizabethan C/D Alexandra's Breakout: Borgia Room Breakout: Georgian Room Breakout: Olympic Room Breakout: Yorkshire Room Breakout: Sussex Room Private Company Track Not-for-Profit Track 7:30 AM Opening Remarks: Doug Braunstein - Chief Financial Officer, JPMorgan Chase & Co., Grand Ballroom Astra Tech 8:00 AM Celgene Corporation Kinetic Concepts, Inc Alkermes, Inc. Biocon Limited Catalent (private company) 8:30 AM Express Scripts Inc. Agilent Technologies Inc. Beckman Coulter Inc. Bio-Rad Laboratories, Inc. Quality Systems Axcan Intermediate Holdings 9:00 AM Roche Holding AG Zimmer Holdings, Inc. Genoptix, Inc. ImmunoGen, Inc Health Net Inc. Merrimack Pharmaceuticals Inc. Vertex Pharmaceuticals Allscripts Healthcare Solutions, 9:30 AM Medicis Pharmaceutical Corp. Lonza Group Ltd Henry Schein Inc. Surgical Care Affiliates Incorporated Inc. 10:00 AM Medtronic, Inc. WellPoint, Inc. Onyx Pharmaceuticals Inc. Sigma-Aldrich Corporation Align Technology Inc.* Symphogen 10:30 AM Room Not Available Medco Health Solutions, Inc. Smith & Nephew plc* Medivation, Inc. Lexicon Pharmaceuticals, Inc. Zeltiq Aesthetics 11:00 AM Room Not Available Merck KGaA Perrigo Company Healthways Incorporated BioMimetic Therapeutics, Inc. Penumbra, Inc. 11:30 AM Room Not Available Dendreon Corporation Gen-Probe Inc. Select Medical Corporation ArthroCare Corporation PTC Therapeutics, Inc. 12:00 PM Luncheon & Keynote: Nancy-Ann DeParle - Counselor to the President and Director of the White House Office of Health Reform, Grand Ballroom Endo Pharmaceuticals Holdings 1:30 PM Room Not Available Amylin Pharmaceuticals Inc.
    [Show full text]
  • Rebateable Manufacturers
    Rebateable Labelers – July 2021 Manufacturers are responsible for updating their eligible drugs and pricing with CMS. Montana Healthcare Programs will not pay for an NDC not updated with CMS. Note: Some manufacturers on this list may have some NDCs that are covered and others that are not. Manufacturer ID Manufacturer Name 00002 ELI LILLY AND COMPANY 00003 E.R. SQUIBB & SONS, LLC. 00004 HOFFMANN-LA ROCHE 00006 MERCK & CO., INC. 00007 GLAXOSMITHKLINE 00008 WYETH PHARMACEUTICALS LLC, 00009 PHARMACIA AND UPJOHN COMPANY LLC 00013 PFIZER LABORATORIES DIV PFIZER INC 00015 MEAD JOHNSON AND COMPANY 00023 ALLERGAN INC 00024 SANOFI-AVENTIS, US LLC 00025 PFIZER LABORATORIES DIV PFIZER INC 00026 BAYER HEALTHCARE LLC 00032 ABBVIE INC. 00037 MEDA PHARMACEUTICALS, INC. 00039 SANOFI-AVENTIS, US LLC 00046 WYETH PHARMACEUTICALS INC. 00049 ROERIG 00051 ABBVIE INC 00052 ORGANON USA INC. 00053 CSL BEHRING L.L.C. 00054 HIKMA PHARMACEUTICAL USA, INC. 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 00065 ALCON LABORATORIES, INC. 00068 AVENTIS PHARMACEUTICALS 00069 PFIZER LABORATORIES DIV PFIZER INC 00071 PARKE-DAVIS DIV OF PFIZER 00074 ABBVIE INC 00075 AVENTIS PHARMACEUTICALS, INC. 00078 NOVARTIS 00085 SCHERING CORPORATION 00087 BRISTOL-MYERS SQUIBB COMPANY 00088 AVENTIS PHARMACEUTICALS 00093 TEVA PHARMACEUTICALS USA, INC. 00095 BAUSCH HEALTH US, LLC Page 1 of 19 Manufacturer ID Manufacturer Name 00096 PERSON & COVEY, INC. 00113 L. PERRIGO COMPANY 00115 IMPAX GENERICS 00116 XTTRIUM LABORATORIES, INC. 00121 PHARMACEUTICAL ASSOCIATES, INC. 00131 UCB, INC. 00132 C B FLEET COMPANY INC 00143 HIKMA PHARMACEUTICAL USA, INC. 00145 STIEFEL LABORATORIES, INC, 00168 E FOUGERA AND CO. 00169 NOVO NORDISK, INC. 00172 TEVA PHARMACEUTICALS USA, INC 00173 GLAXOSMITHKLINE 00178 MISSION PHARMACAL COMPANY 00185 EON LABS, INC.
    [Show full text]